Therapy News and Research

RSS

Targeted therapy as common as chemotherapy at end of life

Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

Spine Revitalizer develops infographic about non-surgical back pain treatment

More than 3 in 4 Americans experience back pain at some point in their life. Thankfully, Spine Revitalizer has released a helpful resource to give basic information for those suffering from back pain.

6 Dec 2012

Maryland P3 Program can improve outcomes of patients with chronic diseases

A new program guide, published by the Centers for Disease Control and Prevention (CDC), features the Maryland Patients, Pharmacists, Partnerships (P3) as an effective model of how health care teams that include pharmacists can improve the outcomes of patients with chronic diseases.

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Scientists evaluate two different strategies to treat Usher syndrome

After years of basic research, scientists at Johannes Gutenberg University Mainz (JGU) are increasingly able to understand the mechanisms underlying the human Usher syndrome and are coming ever closer to finding a successful treatment approach. The scientists in the Usher research group of Professor Dr. Uwe Wolfrum are evaluating two different strategies. These involve either the repair of mutated genes or the deactivation of the genetic defects using agents.

6 Dec 2012

Prescribing opioids lead to admissions for substance abuse treatment and deaths

A Viewpoint article published recently in the Journal of the American Medical Association suggests that the clinical practice of prescribing amphetamines, opioids, and benzodiazepines to treat chronic pain may be contributing to the increase in fatal drug overdoses and the likelihood that those drugs will be diverted to the illegal market.

6 Dec 2012

Tenofovir DF safe and effective in treating adolescents with HBV

A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants.

6 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

Obesity ramps up thoracic surgery costs

Obese patients have significantly increased operating times when undergoing lobectomy for primary lung cancer, show US study results.

5 Dec 2012

Surprising discovery about physical properties of cancer cells

A surprising discovery about the physical properties of cancer cells could help improve a new diagnostic approach - a liquid biopsy - that detects, measures, and evaluates cancer cells in blood.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Arthrobotrys oligospora produces nanoparticles that could kill tumors

Arthrobotrys oligospora doesn't live a charmed life; it survives on a diet of roundworm. But a discovery by a team led by Mingjun Zhang, an associate professor of biomedical engineering at the University of Tennessee, Knoxville, could give the fungus's life more purpose-as a cancer fighter.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Natural killer cell response detrimental to glioblastoma virotherapy

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor.

5 Dec 2012

Revised version of UPLIFT proves successful in preventing epilepsy-related depression

Emory researchers announced results of a new study that has proven successful in the prevention of depression in people diagnosed with epilepsy.

5 Dec 2012

Combination of ketogenic diet and radiation therapy effectively treats malignant gliomas

A team of brain cancer researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has effectively treated brain tumor cells using a unique combination of diet and radiation therapy.

5 Dec 2012

Starting ART for HIV decreases food insecurity among patients in Uganda

Can treatment with modern anti-HIV drugs help fight hunger for HIV-infected patients in Africa? Starting antiretroviral therapy for HIV reduces "food insecurity" among patients in Uganda, suggests a study published online by the journal AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

5 Dec 2012

Baxter enters definitive agreement to acquire Gambro

Baxter International Inc. has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK (approximately $4.0 billion USD at current exchange rates).

From Baxter International Inc. 5 Dec 2012

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.

5 Dec 2012